New Delhi: The Covid-19 vaccine developed by the National Institutes of Health and Moderna Inc. has reportedly begun its trials with volunteers at various United States sites. The medical companies have launched trials for the vaccine consisting of 30,000 subjects.
The companies Pfizer and Moderna got huge funds from the U.S. Government. The Moderna company got a fund of $1 billion to fast-track a vaccine for the coronavirus. Pfizer has received $2 billion which would provide vaccines to 50 million Americans. The vaccine is said to be mRNA based which helps the body to identify and eliminate the virus by using an identical surface.
At the beginning of 2021, it is said that Moderna might produce 500 million to 1 billion doses of the vaccine, whereas Pfizer will produce 1.3 billion doses. There are many other vaccines made by China and Britain’s Oxford University that has also begun smaller final-stage tests in Brazil and other countries.
There are over 150 Covid-19 vaccines that are under development and out of which a few of them have progressed onto human trials. One of the vaccines that have shown great positive results is the one developed by UK pharma company AstraZeneca Plc in partnership with researchers from Oxford University.
Coming to India, the human trial for Covaxin has begun in Odisha. It is being carried out at the Institute of Medical Sciences (IMS) and SUM Hospital in Bhubaneswar. There are five sites in India that are ready for the third and final phase of human trials of the Oxford-AstraZeneca Covid-19 vaccine.